Table 4.
Perioperative management of NOACs (dabigatran and rivaroxaban)—proposal for recommendations from the GIHP (Groupe d'Intérêt en Hémostase Périopératoire) [29].
| Measured concentration | Recommendations |
|---|---|
| <30 ng/mL | Operate |
| 30–200 ng/mL | (i) Wait up to 12 h and obtain new dosage or (if time is not compatible with emergency) (ii) Operate, if abnormal bleeding: antagonise the anticoagulant effect |
| 200–400 ng/mL | (i) Wait up to 12 h and obtain new dosage or (if time is not compatible with emergency) (ii) Maximise delay surgery (iii) Discuss hemodialysis, especially if crcl<50 mL/min (with dabigatran only) (iv) Operate, if abnormal bleeding: antagonise |
| >400 ng/mL | Overdose major haemorrhagic risk Discuss haemodialysis before surgery (with dabigatran only) |